生物技术公司Northwest Biotherapeutics宣布同意收购Advent BioServices-动脉网

Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

CISION 等信源发布 2025-08-28 00:45



可切换为仅中文







BETHESDA, Md.

贝塞斯达，马里兰州

，

Aug. 27, 2025

2025年8月27日

/PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:

NWBO

) (the 'Company' or 'NWBio'), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into an agreement to acquire Advent BioServices Ltd. from its owner, Toucan Holdings LLC. The transaction is expected to close as soon as certain legal conditions are fulfilled.

）（“公司”或“NWBio”），一家正在开发DCVax®个性化免疫疗法用于实体肿瘤癌症的生物技术公司，宣布已达成协议，将从其所有者Toucan Holdings LLC手中收购Advent BioServices Ltd.。预计该交易将在满足某些法律条件后尽快完成。

At closing, Advent will become a wholly owned subsidiary of the Company, and this is expected to enable the Company's operations to become fully integrated. The acquisition is also expected to enhance the Company's positioning for scale-up of operations, and yield important synergies and cost savings. .

在收购结束时，Advent将成为公司的全资子公司，这有望使公司的运营实现完全整合。此次收购还有望提升公司扩大运营规模的能力，并带来重要的协同效应和成本节约。

As part of the acquisition, the Company will receive all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. In addition, 19 million NWBio securities that were previously issued to Advent as payment for contract services will revert back to the Company (13.5 million shares and 5.5 million options).

作为收购的一部分，公司将获得Advent的所有固定资产，包括近年来Advent购置的大量低温储存设备及其他设备。此外，之前发行给Advent作为合同服务付款的1900万股NWBio证券（1350万股和550万期权）将归还给公司。

Certain intellectual property and other intangibles that Advent has acquired will also transfer to the Company..

某些 Advent 已收购的知识产权及其他无形资产亦将转移至公司。

As reported in the Company's recent Form 10-Q, the Company and Advent have been doing strategic planning for some time to consolidate the operations of the London GMP facility and the Sawston GMP facility. The parties have also been planning for increased focus on ramp-up of manufacturing in Sawston, now that years of intensive product and process development work have been completed by Advent for the Marketing Authorization Application (MAA) and the DCVax®-Direct program.

正如公司在最近的10-Q表格中所报告的，公司和Advent一直在进行战略规划，以整合伦敦GMP工厂和索斯顿GMP工厂的运营。各方还计划加大对索斯顿制造能力提升的投入，因为Advent已经为营销授权申请（MAA）和DCVax®-Direct项目完成了多年密集的产品和工艺开发工作。

Joining the two companies is expected to facilitate implementation of these plans..

两家公司合并有望促进这些计划的实施。

The consideration for the acquisition will be paid in installments over two years, beginning 90 days after the acquisition agreement, with potential acceleration after regulatory approval of the Company's DCVax®-L product. The consideration will include a payment of £1.4 million, and payment of the net amount of accounts payable ('Net AP') due from the Company to Advent as of the date of the acquisition agreement for services already performed by Advent under the existing service contracts and Statements of Work (SOWs) that have been reported in the Company's public filings.

收购款项将在两年内分期支付，自收购协议签订后90天开始支付，并可能在公司DCVax®-L产品获得监管批准后加速支付。收购款项将包括140万英镑的支付，以及公司根据现有服务合同和工作说明书（SOW）已由Advent履行的服务所产生的应付账款净额（“净应付账款”），该金额截至收购协议签署日已在公司的公开文件中报告。

The Net AP payable by the Company will be the outstanding accounts payable on the agreement date reduced by certain adjustments between the parties..

公司应付的净应付账款将是协议日期未清偿的应付账款减去双方之间的某些调整。

'This is an exciting day for the Company, entering into an agreement to bring its manufacturing and product development operations in-house,' commented

“这是一个令人兴奋的日子，公司达成了协议，将把其制造和产品开发业务纳入内部，”评论道。

Linda Powers

琳达·鲍尔斯

, the Company's CEO. 'We believe this is an opportune time to join forces under one roof, integrating our teams, streamlining our processes, increasing our efficiency and preparing for potential substantial scale-up of our capacity.'

，公司首席执行官。“我们相信现在是整合团队、简化流程、提高效率并在一个屋檐下联合起来的有利时机，为潜在的大规模产能提升做好准备。”

About Northwest Biotherapeutics

关于西北生物治疗公司

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax.

西北生物治疗公司是一家生物技术公司，专注于开发个性化免疫治疗产品，旨在比现有治疗方法更有效地治疗癌症，且不会产生与化疗相关的毒性，并具有成本效益。该公司拥有DCVax的广泛平台技术。

dendritic cell-based vaccines. The Company's lead program involves DCVax

基于树突细胞的疫苗。公司的主要项目涉及DCVax

-L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an 'orphan disease.' The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review.

-L治疗胶质母细胞瘤（GBM）。GBM是最具侵袭性和致命性的原发性脑癌，属于“孤儿病”。公司已经完成了针对GBM的DCVax-L的331名患者的III期试验，在科学会议上展示了结果，将结果发表在《JAMA肿瘤学》上，并提交了在英国上市批准的MAA。该MAA目前正在审查中。

The Company has also developed DCVax.

公司还开发了DCVax。

-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and plans to pursue Phase II trials this year. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of

-针对无法手术的实体肿瘤癌症。它已经完成了40名患者的I期试验，并计划在今年进行II期试验。该公司之前与大学合作进行了DCVax-L针对晚期卵巢癌的I/II期试验。

Pennsylvania

宾夕法尼亚州

。

Disclaimer

免责声明

Statements made in this news release that are not historical facts, including statements concerning plans for DCVax

本新闻稿中发表的非历史事实的声明，包括有关DCVax计划的声明

are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'expect,' 'believe,' 'intend,' 'design,' 'plan,' 'continue,' 'may,' 'will,' 'anticipate,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

这些陈述是根据1995年《私人证券诉讼改革法案》所定义的前瞻性陈述。诸如“预期”、“相信”、“打算”、“设计”、“计划”、“继续”、“可能”、“将”、“预计”等词语以及类似表达旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词语。

Actual results may differ materially from those projected in any forward-looking statement. Readers should not rely upon forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those anticipated, including, without limitation, risks related to delays or uncertainties in regulatory processes and decisions, risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will be viewed as demonstrating safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ('SEC') filings.

实际结果可能与任何前瞻性声明中预测的结果存在重大差异。读者不应依赖前瞻性声明。有许多重要因素可能导致实际结果与预期结果存在重大差异，包括但不限于与监管流程和决策的延迟或不确定性相关的风险、与公司能否实现第三方及时履约能力相关的风险、与公司产品是否会被视为展示安全性和有效性相关的风险、与公司持续筹集额外资本能力相关的风险，以及公司向美国证券交易委员会（“SEC”）提交文件中包含的其他风险。

Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual plans, results or timelines to differ materially from those projected in any forward-looking statement.

有关上述风险因素及其他因素的更多信息，包括可能影响公司结果的风险因素，已包含在其向美国证券交易委员会（SEC）提交的文件中。最后，可能还存在其他上述未提及或未包含在公司SEC文件中的因素，这些因素可能导致实际计划、结果或时间表与任何前瞻性声明中预测的内容有重大差异。

The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws..

公司概不承担因新信息、未来事件或发展而更新任何前瞻性陈述的义务，但证券法要求的除外。

CONTACTS

联系人

Northwest Biotherapeutics

西北生物治疗公司

Dave Innes

戴夫·英尼斯

804-513-6758

dinnes@nwbio.com

Logo -

标志 -

https://mma.prnewswire.com/media/325355/northwest_biotherapeutics__inc__logo.jpg